Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Christopher Roberts
AddedFeb 15, 2024
UpdatedMay 31, 2026
Christopher Roberts

Christopher Roberts

CEO, Civetta Therapeutics

CrunchbaseLinkedInThe Org

Christopher Roberts's Career

Civetta Therapeutics
Civetta Therapeutics

Cambridge, MA, US

CEO· C-Suite · Management
GRO Biosciences
GRO Biosciences

Boston, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Christopher Roberts's Career

Civetta Therapeutics
Civetta Therapeutics
Series A$53M392019Cambridge, MA, US
CEO· C-Suite · Management

Leadership at Civetta Therapeutics

Erich FischerErich FischerCo-Founder
William SellersWilliam SellersCo-Founder

Similar to Civetta Therapeutics

Cedilla TherapeuticsCedilla TherapeuticsCambridge, MA, USTherapeuticsest. 2018Cedilla TherapeuticsCambridge, MA, US · est. 2018

Cedilla Therapeutics: A Massachusetts-based biotech firm innovating small molecule disease treatments.

Series B · $138.8M45
Palm TherapeuticsPalm TherapeuticsSan Diego, CA, USCancer Treatmentest. 2018Palm TherapeuticsSan Diego, CA, US · est. 2018

Revolutionizing cancer treatment with next-gen root-level therapeutics.

Angel · $991.1k7
Traws PharmaTraws PharmaNewtown, PA, USCancer Treatmentsest. 1998Traws PharmaNewtown, PA, US · est. 1998

US-based Onconova Therapeutics, Inc. pioneers novel cancer treatments through small molecule drug discovery.

Public · $177.9M17
Synnovation TherapeuticsSynnovation TherapeuticsWilmington, DE, USOncology Therapiesest. 2021Synnovation TherapeuticsWilmington, DE, US · est. 2021

Synnovation Therapeutics: Precision oncology firm specializing in small molecule therapies for cancer.

Series A · $139M18
GRO Biosciences
GRO Biosciences
Series A$32.3M442016Boston, MA, US
Board Member· Board

Leadership at GRO Biosciences

Rakhshita DharRakhshita DharBoard Member
Bruce BeutelBruce BeutelBoard Member
Nicole PaulkNicole PaulkBoard Member
Ross ThyerRoss ThyerCo-Founder
Christopher GreggChristopher GreggCo-Founder
Daniel J MandellDaniel J MandellCo-Founder

Similar to GRO Biosciences

Grove BiopharmaGrove BiopharmaChicago, IL, USBiotherapeuticsest. 2020Grove BiopharmaChicago, IL, US · est. 2020

Grove: A preclinical biotech startup innovating biotherapeutics for unmet medical needs.

Seed · $10.5M8
Groove BiopharmaGroove BiopharmaSeattle, WA, USDrugs, Therapeuticsest. 2008Groove BiopharmaSeattle, WA, US · est. 2008

Groove Biopharma: Pioneering microRNA therapeutics for cancer, fibrosis, and infectious diseases.

Series B · $9.9M6
AI ProteinsAI ProteinsBoston, MA, USProtein Therapeuticsest. 2021AI ProteinsBoston, MA, US · est. 2021

AI Proteins: A biotech firm specializing in the design and engineering of synthetic mini protein therapeutics.

Series B · $18.2M44
ProFound TherapeuticsProFound TherapeuticsCambridge, MA, USTherapeuticsest. 2022ProFound TherapeuticsCambridge, MA, US · est. 2022

ProFound Therapeutics: Innovating impactful disease understanding and therapeutic creation.

Series A · $75M35

People Similar to Christopher Roberts

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoShal JacobovitzShal JacobovitzBoard Member · CleneTom RobertsTom RobertsCEO · New Republic PartnersBradley DodsonBradley DodsonCEO · CiveoChristopher DoyleChristopher DoyleBoard Member · Civitas ResourcesJOHN J SEMANJOHN J SEMANCEO · Canget BioTekpharmaBrigette RobertsBrigette RobertsCEO · AI Therapeutics